CG
GILD icon

Cynosure Group’s Gilead Sciences GILD Stock Holding History

Cynosure Group’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Buy
+4,862
New +$641K 0.09% 127

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cynosure Group's GILD Position: Q2 2026 in Review

Cynosure Group opened a new position in Gilead Sciences (GILD) in Q2 2026: 4,862 shares worth $614K. The stake represents 0.09% of the portfolio and ranks #127 among its holdings.

2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Cynosure Group held 4,862 shares of Gilead Sciences worth $614K as of Q2 2026.
  • Gilead Sciences was a new Cynosure Group position in Q2 2026.
  • Gilead Sciences made up 0.09% of Cynosure Group's portfolio in Q2 2026, its #127 holding.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Cynosure Group's 13F filing for Q2 2026, filed 5 Aug 2026.